RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902 I almost doubled my position today. Strange to see the SP fall on such a news.
Looking at the trial protocol on clinicaltrials.gov, I noticed an important aspect that will give the scientists involved in the trial a very early indication to know if the PDC works as intended, at least to bond with receptors. They will monitor free docetaxel in the blood after injection. If they find almost nothing, it will be a good indication that the PDC is stable in the bloodstream and that it bonds with sortilin and introduced inside the cells bearing this receptor. They will also do dosing of TH1902 in the blood (PK profile). So I think that well before safety data, they will know if the PDC (TH1902) is working as planned as far as not staying in the bloostream intil enzymatic degradation. Proof of releasing free docetaxel into cancer cells is another story. But the proof that it is not degraded in the bloodstream would be a very good first step towards proof of efficacy.